Affordable Access

deepdyve-link
Publisher Website

Performance evaluation of a fully closed real-time PCR platform for the detection of KRAS p.G12C mutations in liquid biopsy of patients with non-small cell lung cancer.

Authors
  • Gragnano, Gianluca1
  • Nacchio, Mariantonia1
  • Sgariglia, Roberta1
  • Conticelli, Floriana1
  • Iaccarino, Antonino1
  • De Luca, Caterina1
  • Troncone, Giancarlo2
  • Malapelle, Umberto1
  • 1 Public Health, University of Naples Federico II, Naples, Italy. , (Italy)
  • 2 Public Health, University of Naples Federico II, Naples, Italy [email protected] , (Italy)
Type
Published Article
Journal
Journal of Clinical Pathology
Publisher
BMJ
Publication Date
May 01, 2022
Volume
75
Issue
5
Pages
350–353
Identifiers
DOI: 10.1136/jclinpath-2021-207416
PMID: 33649142
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Whenever tissue sample is not available, non-small cell lung cancer (NSCLC) biomarker testing is performed with liquid biopsy. The Kirsten rat sarcoma viral oncogene homolog (KRAS) p.G12C mutation is a novel target in patients with NSCLC. In this study, 33 NSCLC frozen plasma samples, previously characterised for KRAS mutational status by next generation sequencing (NGS), were processed by the fully automated Idylla KRAS assay. In 30/33 cases, archival matched cell-free DNA (cfDNA) was also directly pipetted in the cartridge. Overall, 30/33 plasma and 28/30 cfDNA samples yielded valid results. In 29/30 of KRAS p.G12C mutant plasma samples and 26/28 of cfDNA, Idylla confirmed the NGS results. In conclusion, the Idylla NSCLC KRAS liquid biopsy assay may represent a reliable tool to assess KRAS p.G12C mutation. © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Report this publication

Statistics

Seen <100 times